Beating the Clock in T-cell Acute Lymphoblastic Leukemia

Clin Cancer Res. 2017 Feb 15;23(4):873-875. doi: 10.1158/1078-0432.CCR-16-2825. Epub 2016 Dec 22.

Abstract

CDK4/6 inhibition was synergistic with dexamethasone and everolimus but antagonistic with conventional chemotherapy in T-cell acute lymphoblastic leukemia (T-ALL) preclinical models. Cyclin-dependent kinase inhibition in combination with glucocorticoids and mTOR inhibition offers a unique therapeutic opportunity in T-ALL. Clin Cancer Res; 23(4); 873-5. ©2016 AACRSee related article by Pikman et al., p. 1012.

MeSH terms

  • Cell Line, Tumor
  • Cyclin-Dependent Kinase 4 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 4 / genetics
  • Dexamethasone / therapeutic use
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Synergism*
  • Everolimus / therapeutic use
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Protein Kinase Inhibitors / therapeutic use
  • Signal Transduction
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / genetics

Substances

  • Protein Kinase Inhibitors
  • Dexamethasone
  • Everolimus
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • CDK4 protein, human
  • Cyclin-Dependent Kinase 4